background cellculturederiv cc influenza vaccine product method could provide benefit classic embryonatedegg technology include higher caps faster creation supply meet demand ccinactiv splitviru indonesian derive eb cell line hereafter chn investing phase random blind studi health adult n receive dose day either investing Âµg hemagglutinin antigen ha adj system plain embryonatedeggderiv vaccine placebo ass effect immunogen perform use center biology value research accept criterion dose safety ass month result asadjuv elicit homolog hemagglutin inhibit antibody response satisfy persist immune driftvari strain demons vaccinerel serious adverse event report formal contain appear similar license eggderiv control concur feasible product immunogen accept profil spare achieve combine might contribute rapid access event ahn tandem clinic trial register not 